北京招聘

Job Responsibility

1.  To lead the strategic and operation planning of the statistical contributions to the Development Plans, Regulatory Strategy and Submissions.

2.  Leadership on the product so that all work is carried out with regards to Company standards and external regulations.

3.  Developing design options and providing high quality decision support Quantifying the benefit, risk, value and uncertainty of the emerging product profile.

4.  Setting the standards (and enforcing compliance) for statistical work within the product;

5.  Holding CRO/Partners accountable for the high quality standards of their deliverable Represent Company and Statistics to Health Authorities for specific projects/indications;

6.  Investigate and implement statistical approaches, for relevant statistical issues and/or regulatory guidance and/or value demonstration.

7.  Maintains understanding and awareness on new methodologies, therapy area and  Development initiatives

8.  Provide leadership and direction to improvement projects/activities/initiatives and drive the implementation of best practice across the group.

9.  Develops contacts with international opinion leaders, consultants and collaborative groups.

10. Ensure drug projects are successfully delivered in terms of scientific leadership and resourcing

Education, Qualification, Skills and Experience

1.  MSc/PhD in Statistics，Mathematics, or other related data science majors

2.  Excellent communication skills and ability to build strong relationships

3.  Collaborative - has the energy to work with global & across functional boundaries both internally and externally

4.  Ability to apply statistical expertise to complex problems, problem solving and quality focus

5. Good spoken English capability

    迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心，设立于中国上海，是阿斯利康全球四个研发中心之一（另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡）；是国际一流、高产出的创新药研发机构，拥有全球领先的转化医学和新药分子设计与筛选技术平台；在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。
    迪哲医药，于2017年10月独立运营，是一家研发驱动型生物医药企业，致力于全球创新药物（First-in-class/ Best-in-class）探索、研发以及商业化。
    详情请点击公司官方网站：**************************/

Dizal Pharma
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.
The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.